One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
ObsEva SA logo
ObsEva SA OBSV

ObsEva SA Financial Ratios 2021-2011 | OBSV

Annual Financial Ratios ObsEva SA

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- -1.9 -1.5 -6.5 -5.3 -11.5 - - - - -

EPS

- -1.7 -2.5 -1.9 -2.2 -1.4 -1.9 - - - -

EV (Enterprise Value)

- 182 M 147 M 380 M 256 M 332 M -47.4 M 3.29 M - - -

EBITDA per Share

- -1.79 -2.44 -1.92 -2.26 -1.02 - - - - -

EV/EBITDA

- -1.9 -1.1 -4.7 -3.6 -10.7 - - - - -

PEG

- -0.08 0.05 -0.43 0.04 0.22 - - - - -

P/B

- 18.7 3.3 3.4 2.9 9.7 - - - - -

P/CF

- -2.2 -1.7 -7.8 -5.8 -12.2 - - - - -

ROE %

- -993.13 -222.22 -52.22 -54.57 -83.80 - - - - -

ROA %

- -126.77 -104.66 -45.82 -49.49 -66.34 - - - - -

ROCE %

- -182.20 -126.78 -51.26 -53.63 -77.54 - - - - -

Current Ratio

- 1.7 3.8 8.6 12.0 4.3 - - - - -

All numbers in USD currency

Quarterly Financial Ratios ObsEva SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - - - - - - - - - - -0.8 - - - -0.49 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - - - - - - - - - - - -0.79 - - - -0.48 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

- - - - - - - - - - -36.86 -73.71 -73.71 -36.86 -47.15 -20.59 -20.59 -10.30 -10.30 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

- - - - - - - - - - -27.04 -54.08 -54.08 -27.04 -27.04 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - - - - - - - - - -34.55 -69.11 -69.11 -34.55 -44.85 -20.60 -20.60 -10.30 -10.30 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company ObsEva SA, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.14 -2.56 % $ 61.2 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.3 -0.46 % $ 50 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.55 0.85 % $ 286 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 17.02 0.98 % $ 2.29 B canadaCanada
iBio iBio
IBIO
$ 0.71 -1.28 % $ 73.9 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.21 -0.37 % $ 92.2 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
$ 1.51 -5.03 % $ 148 M usaUSA
Immunome Immunome
IMNM
$ 17.89 -0.54 % $ 1.56 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 1.57 9.03 % $ 6.54 M canadaCanada
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 0.88 -1.82 % $ 41.3 M usaUSA
Innoviva Innoviva
INVA
$ 21.06 1.91 % $ 1.42 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 13.78 -2.24 % $ 4.92 M usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 424.81 1.06 % $ 33.2 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.35 0.62 % $ 422 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
$ 20.39 5.79 % $ 7.52 B usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 308.16 1.53 % $ 5.96 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 68.11 -0.65 % $ 13 B usaUSA
Annovis Bio Annovis Bio
ANVS
$ 0.95 -4.92 % $ 19.5 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 43.75 2.58 % $ 3.77 B usaUSA
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.46 2.81 % $ 530 M usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.36 -1.89 % $ 1.77 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.88 3.01 % $ 1.65 B usaUSA
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 437.59 0.77 % $ 9.82 B usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.69 -10.37 % $ 96.1 M usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 83.44 3.79 % $ 4.19 B usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.49 -7.45 % $ 470 K usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.23 1.25 % $ 987 M usaUSA
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 70.52 -0.18 % $ 523 M usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
$ 0.9 -6.16 % $ 13.8 M usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 7.5 3.69 % $ 1.08 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 1.66 -2.92 % $ 9.09 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 145.91 2.25 % $ 14.5 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Biogen Biogen
BIIB
$ 252.25 0.62 % $ 37 B usaUSA
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.2 -4.35 % $ 18.6 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 37.17 -0.12 % $ 627 M usaUSA
Nkarta Nkarta
NKTX
$ 1.87 4.47 % $ 138 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.37 -2.14 % $ 27.7 M usaUSA